[Clinical and bacteriological efficacy and tolerability of meropenem in the treatment of bronchopulmonary affections in children with mucoviscidosis].
Meropenem (in combination with amikacin) was used in the treatment of children and adolescents with mucoviscidosis and severe exacerbation of bronchopulmonary affections. The drug showed satisfactory clinical and moderate bacteriological effects (48.3%) as dependent on the severity and duration of the disease and the microbial flora. Meropenem was well tolerated: no side effects were observed during the treatment, whereas it was used in high doses (60-105 mg/kg daily).
S Iu
SIu
Semykin
S S
SS
Postnikov
L V
LV
Perederko
S V
SV
Polikarpova
L G
LG
Dubovik
D000583:Amikacin / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001996:Bronchopneumonia / Q000188:drug therapy* / Q000209:etiology; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D000077731:Meropenem; D013845:Thienamycins / Q000627:therapeutic use*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000583:Amikacin; D000077731:Meropenem